Summary

For high-risk atrial fibrillation patients who are unsuitable for Vitamin K antagonist (eg, warfarin) therapy, dual antiplatelet therapy with clopidogrel and aspirin reduces the risk of major vascular events compared with aspirin alone, according to findings from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE]-A trial [NCT000249873].